Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group

Conclusion
In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.

Source: European Respiratory Journal - August 10, 2022 Category: Respiratory Medicine Authors: Hermine, O., Mariette, X., Porcher, R., Resche-Rigon, M., Tharaux, P.-L., Ravaud, P., on behalf of the CORIMUNO-19 Collaborative Group Tags: Respiratory infections and tuberculosis Original Articles: Respiratory infection and COVID-19 Source Type: research